share_log

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144:拟议出售证券
美股SEC公告 ·  05/14 16:33
Moomoo AI 已提取核心信息
Recursion Pharmaceuticals, Inc. Director Blake Borgeson is set to sell 20,054 Class A shares of the company, with an aggregate market value of $202,934.74, on 05/14/2024. These shares were originally acquired on 09/01/2016 as founders shares, a form of compensation from the issuer. This planned sale follows a series of transactions over the past three months, where a total of 94,503 shares were sold for gross proceeds of $984,984.41.
Recursion Pharmaceuticals, Inc. Director Blake Borgeson is set to sell 20,054 Class A shares of the company, with an aggregate market value of $202,934.74, on 05/14/2024. These shares were originally acquired on 09/01/2016 as founders shares, a form of compensation from the issuer. This planned sale follows a series of transactions over the past three months, where a total of 94,503 shares were sold for gross proceeds of $984,984.41.
Recursion Pharmicals, Inc.董事布莱克·博格森定于2024年5月14日出售该公司的20,054股A类股票,总市值为202,934.74美元。这些股票最初于2016年1月9日作为创始人股票收购,这是发行人补偿的一种形式。此次计划出售是在过去三个月进行的一系列交易之后进行的,共出售了94,503股股票,总收益为984,984.41美元。
Recursion Pharmicals, Inc.董事布莱克·博格森定于2024年5月14日出售该公司的20,054股A类股票,总市值为202,934.74美元。这些股票最初于2016年1月9日作为创始人股票收购,这是发行人补偿的一种形式。此次计划出售是在过去三个月进行的一系列交易之后进行的,共出售了94,503股股票,总收益为984,984.41美元。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息